Antibiotics for the Treatment of Febrile Children with Neutropenia and Cancer

Marc Rubin, Philip A. Pizzo, Jerry L. Shenep, Walter T. Hughes

Research output: Contribution to journalLetterpeer-review

Abstract

To the Editor: The question of whether vancomycin should be included routinely in the initial empirical antibiotic regimen for febrile, neutropenic patients with cancer is important and relevant. Gram-positive organisms are increasing in incidence, and many are resistant to or poorly covered by most regimens that do not contain vancomycin. Thus, some authorities have recommended that vancomycin be part of the initial therapy. On the other hand, vancomycin should not be overused, because it is expensive, it is potentially toxic, and it can be associated with the emergence of resistant organisms. In addition, certain of the beta-lactam–resistant gram-positive organisms, such.

Original languageEnglish (US)
Number of pages1
JournalNew England Journal of Medicine
Volume320
Issue number14
DOIs
StatePublished - Apr 6 1989

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antibiotics for the Treatment of Febrile Children with Neutropenia and Cancer'. Together they form a unique fingerprint.

Cite this